The journal’s chief editor says new articles are held out of MEDLINE and PubMed Central during a review, preventing their appearance in PubMed while the review continues.
Newly published Scientific Reports articles are not entering MEDLINE or PubMed Central while the US National Library of Medicine (NLM) reviews the journal, chief editor Rafal Marszalek said in an 20 October 2026 email. That means the new content will not appear in PubMed during the pause. Retraction Watch disclosed the email on 30 October.
Scientific Reports is published by Springer Nature. Richard White, vice president of publishing for its portfolio, said the journal had grown significantly since its launch and initial NLM indexing 15 years earlier. He said the publisher remained committed to high quality standards and was working with NLM to provide updated information it needed.
The three services serve different purposes. MEDLINE, compiled by NLM, stores article references and related information about biomedical and life-sciences research. PubMed is NLM’s free searchable database of citations and abstracts: it includes MEDLINE records and additional material, including citations from PubMed Central. PubMed Central holds full articles, while PubMed records can link readers to full text elsewhere.
At the time of the October 30 report, the latest Scientific Reports articles in PubMed carried a publication date of 15 September 2026. The report also showed a gap between the journal’s publication total and its PubMed count.
| Measure | Articles |
|---|---|
| Published, as listed on the journal’s website |
| 41,122 |
| In PubMed, excluding errata and retraction notices | 28,593 |
Researcher Tom Lahey maintains tools based on PubMed data. By his count, Scientific Reports had the most articles indexed in PubMed each year since 2019. After noticing unusually low counts for 2 consecutive months, he asked NLM about the slowdown. The PubMed team directed him to the publisher, and Marszalek’s reply disclosed the review.
NLM’s policy, quoted in the October 30 report, says it reevaluates journals after significant changes and monitors publication practices such as annual article volume and article types. Marszalek did not identify the specific reason for this review, and NLM had not answered questions about its reason or expected duration. The policy gives a typical reevaluation period of 7 to 10 months, not a confirmed timetable for Scientific Reports.
Marszalek said he expected indexing to resume after the review, including articles published during the pause. That is the editor’s expectation, not a confirmed outcome or timetable.
The approval covers adults with recurrent respiratory papillomatosis, whose airway growths can require repeated surgery. Further trials must verify the treatment’s clinical benefit.
3 min
President Rodrigo Paz signed the decree on 31 October 2026, enabling resource mobilization and additional rescue-team deployments, with coordination among national and regional authorities, the armed forces and police.
2 min
Specific Flebogamma DIF, Yimmugo and Gamunex batches have already been withdrawn in certain EU member states after allergic-reaction clusters. EMA says the new review covers all human normal immunoglobulins to assess whether further safeguards are needed.
3 min
